Literature DB >> 33766049

Policy disparities in response to the first wave of COVID-19 between China and Germany.

Yuyao Zhang1, Leiyu Shi2, Haiqian Chen1, Xiaohan Wang1, Gang Sun3,4.   

Abstract

OBJECTIVE: Our research summarized policy disparities in response to the first wave of COVID-19 between China and Germany. We look forward to providing policy experience for other countries still in severe epidemics.
METHODS: We analyzed data provided by National Health Commission of the People's Republic of China and Johns Hopkins University Coronavirus Resource Center for the period 10 January 2020 to 25 May 252,020. We used generalized linear model to evaluate the associations between the main control policies and the number of confirmed cases and the policy disparities in response to the first wave of COVID-19 between China and Germany.
RESULTS: The generalized linear models show that the following factors influence the cumulative number of confirmed cases in China: the Joint Prevention and Control Mechanism; locking down the worst-hit areas; the highest level response to public health emergencies; the expansion of medical insurance coverage to suspected patients; makeshift hospitals; residential closed management; counterpart assistance. The following factors influence the cumulative number of confirmed cases in Germany: the Novel Coronavirus Crisis Command; large gathering cancelled; real-time COVID-19 risk assessment; the medical emergency plan; schools closure; restrictions on the import of overseas epidemics; the no-contact protocol.
CONCLUSIONS: There are two differences between China and Germany in non-pharmaceutical interventions: China adopted the blocking strategy, and Germany adopted the first mitigation and then blocking strategy; China's goal is to eliminate the virus, and Germany's goal is to protect high-risk groups to reduce losses. At the same time, the policies implemented by the two countries have similarities: strict blockade is a key measure to control the source of infection, and improving medical response capabilities is an important way to reduce mortality.

Entities:  

Keywords:  COVID-19; China; Germany; Global health equity; Nonpharmaceutical intervention

Mesh:

Year:  2021        PMID: 33766049      PMCID: PMC7993854          DOI: 10.1186/s12939-021-01424-3

Source DB:  PubMed          Journal:  Int J Equity Health        ISSN: 1475-9276


  6 in total

Review 1.  European and United Kingdom COVID-19 pandemic experience: The same but different.

Authors:  W D Carroll; V Strenger; E Eber; F Porcaro; R Cutrera; D A Fitzgerald; I M Balfour-Lynn
Journal:  Paediatr Respir Rev       Date:  2020-07-04       Impact factor: 2.726

2.  Risk, resilience, psychological distress, and anxiety at the beginning of the COVID-19 pandemic in Germany.

Authors:  Moritz Bruno Petzold; Antonia Bendau; Jens Plag; Lena Pyrkosch; Lea Mascarell Maricic; Felix Betzler; Janina Rogoll; Julia Große; Andreas Ströhle
Journal:  Brain Behav       Date:  2020-07-07       Impact factor: 2.708

3.  Endothelial cell infection and endotheliitis in COVID-19.

Authors:  Zsuzsanna Varga; Andreas J Flammer; Peter Steiger; Martina Haberecker; Rea Andermatt; Annelies S Zinkernagel; Mandeep R Mehra; Reto A Schuepbach; Frank Ruschitzka; Holger Moch
Journal:  Lancet       Date:  2020-04-21       Impact factor: 79.321

4.  How we should respond to the Coronavirus SARS-CoV-2 outbreak: A German perspective.

Authors:  F Jung; V Krieger; F T Hufert; J-H Küpper
Journal:  Clin Hemorheol Microcirc       Date:  2020       Impact factor: 2.375

Review 5.  Fangcang shelter hospitals: a novel concept for responding to public health emergencies.

Authors:  Simiao Chen; Zongjiu Zhang; Juntao Yang; Jian Wang; Xiaohui Zhai; Till Bärnighausen; Chen Wang
Journal:  Lancet       Date:  2020-04-02       Impact factor: 79.321

6.  An interactive web-based dashboard to track COVID-19 in real time.

Authors:  Ensheng Dong; Hongru Du; Lauren Gardner
Journal:  Lancet Infect Dis       Date:  2020-02-19       Impact factor: 25.071

  6 in total
  2 in total

Review 1.  The Advantages of the Zero-COVID-19 Strategy.

Authors:  Zhaohui Su; Ali Cheshmehzangi; Dean McDonnell; Junaid Ahmad; Sabina Šegalo; Yu-Tao Xiang; Claudimar Pereira da Veiga
Journal:  Int J Environ Res Public Health       Date:  2022-07-19       Impact factor: 4.614

2.  Clinical characteristics of the delta variant of COVID-19 in Jingmen, China.

Authors:  Fangfang Bie; Wensheng Yuan; Yafeng Chen; Qijun Gao
Journal:  Medicine (Baltimore)       Date:  2022-09-23       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.